enoximone

Enoximone is a selective phosphodiesterase type 3 (PDE3) inhibitor with positive inotropic and vasodilator properties, used primarily for the short-term treatment of congestive heart failure. It increases cardiac contractility and dilates blood vessels without significantly increasing myocardial oxygen consumption. The drug acts by inhibiting PDE3, leading to increased intracellular cyclic AMP levels, which enhances calcium flux in cardiac muscle cells and promotes vascular smooth muscle relaxation. Enoximone is administered intravenously or orally, has a bioavailability of about 50%, is metabolized hepatically, and has an elimination half-life of approximately 4–10 hours. While development was discontinued in the U.S., it remains approved for use in several countries including the UK[1][2][4][5][6].

Brand names

Perfan

Other names

FenoximoneEnoximona